A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-14-0791
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Gasdermins Deliver a Deadly Punch to Cancer

Cell Research
Cell BiologyMolecular Biology
2020English

Targeting the HER Family With Pan-Her Effectively Overcomes Resistance to Cetuximab

European Journal of Cancer
Cancer ResearchOncology
2016English

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Correction: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

PLoS ONE
Multidisciplinary
2015English

Targeting Autophagy for Overcoming Resistance to Anti-Egfr Treatments

Cancers
Cancer ResearchOncology
2019English

Clinical Significance of EGFR, Her-2 and EGF in Oral Squamous Cell Carcinoma: A Case Control Study

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2010English

2-Triazenoazaindoles: A Novel Class of Triazenes Inducing Transcriptional Down-Regulation of EGFR and HER-2 in Human Pancreatic Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2011English

Packing a Punch

Food Science and Technology
Food Science
2019English

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel in Vivo Model of Acquired Cetuximab Resistance

Clinical Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy